Matinas BioPharma Announces 1-for-15 Reverse Stock Split

What Happened

• Matinas BioPharma Holdings, Inc. (MTNB) filed an 8-K reporting a Certificate of Amendment that effects a one-for-fifteen (1:15) reverse stock split of its common stock. The Certificate of Amendment was filed with the Delaware Secretary of State on September 25, 2026 and became effective at 12:01 a.m. Eastern Time on September 28, 2026. The company says it expects the Common Stock to trade on a reverse-split-adjusted basis on the NYSE American when the market opens on September 28, 2026, subject to the Exchange’s approval.

Key Details

• Reverse split ratio: 1-for-15 (every 15 shares converted into 1 share).
• Effective timing: Certificate filed Sept 25, 2026; effective 12:01 a.m. ET on Sept 28, 2026.
• CUSIP change: new CUSIP for Common Stock is 576810402.
• Fractional shares: no fractional shares issued; holders entitled to a proportional cash payment for any fractional interest.
• Other effects: par value and authorized number of shares unchanged; outstanding options, warrants and convertible securities were adjusted per their terms.
• Approvals: stockholders approved the amendment at the June 23, 2025 annual meeting; the Board approved filing on Sept 16, 2026. Certificate of Amendment is filed as Exhibit 3.1.

Why It Matters

• A reverse stock split reduces the number of outstanding shares and increases the per-share trading price proportionally, but does not change any stockholder’s percentage ownership (except for cash-outs of fractional shares). For investors, this affects share count and per-share metrics (price, market cap per share) while leaving ownership percentages intact.
• The adjustment of options, warrants and convertibles can change per-share strike or conversion terms—holders should review their agreements for the specific post-split impacts.
• The new CUSIP and expected NYSE American trading on a split-adjusted basis are operational items investors should note for trading, recordkeeping and tax reporting.